Pharma

Comparing Generic Drug Markets in Europe and the United States: Prices, Volumes, and Spending

Originally published by Er J. Wouters, Panos G. Kavanos, Martin McKee in The Milbank Quarterly, 95: 554–601 under a Creative Commons License. Abstract Policy Points: Our study indicates that there are opportunities… The post Comparing Generic Drug Markets in Europe and the United States: Pric ...

Which pharmaceutical companies have the most drug patents in Israel?

This chart shows the pharmaceutical companies with the most patents in Israel. Patents must be filed in each country (or, in some cases regional patent office) where patent protection is… The post Which pharmaceutical companies have the most drug patents in Israel? appeared first on DrugPatentWat ...

Which drugs have the most supplementary protection certificates?

This chart shows the drugs with the most supplementary protection certificates (SPCs). SPCs are used in European Union and select others to encourage pharmaceutical innovation by compensating for the long… The post Which drugs have the most supplementary protection certificates? appeared first on ...

Big Pharma’s Drug War: Innovative vs. Generic and Biosimilar Drugs

Big Pharma’s Drug War: Innovative vs. Generic and Biosimilar Drugs By Wayne Schnarr When I started my job in 1989 as a lobbyist for the Canadian generic drug industry, I thought that my job would be accumulating and organizing facts in a logical manner to present to consumer groups, governments ...

L.PR.B : DBRS Reduces Trend to “Stable”

DBRS has announced that it has: confirmed the ratings of Loblaw Companies Limited (Loblaw) and Shoppers Drug Mart Corporation (guaranteed by Loblaw) at BBB after the announcement that Choice Properties Real Estate Investment Trust (CP REIT; rated BBB by DBRS) has entered into an agreement to acquir ...

Acasti Pharma has 194% upside, Echelon Wealth says

All eyes will be on upcoming Phase III drug trials for Acasti Pharma’s (TSXV:ACST) cardiovascular drug, CaPre, which could be a big revenue generator, says analyst Douglas Loe of Echelon Wealth Partners, who maintains his “Speculative Buy” rating on the stock and a target price of $4.00. Lava ...

Bloom Burton & Co. Announces the 2018 Bloom Burton Award Gala

Annual Award Recognizes the Most Significant Contributor to Canada’s Innovative Healthcare Industry  TORONTO, February 12, 2018 – Bloom Burton & Co. (“Bloom Burton”) is thrilled to announce the 2018 Bloom Burton Award Gala, to be held at the Four Seasons Hotel in Toronto, Ontario, Canada ...

CannTrust Holdings is undervalued, GMP Securities says

With recreational marijuana still yet to become a reality in Canada, it’s not easy picking the winners from the herd of contenders, but CannTrust Holdings (CSE:TRST) stands out, says GMP Securities analyst Martin Landry, with reason number one being that TRST has proven to be profitable. “CannT ...

Cronos Group gets price target raise at Canaccord Genuity

He’s not yet ready to recommend the stock, but recent developments have Canaccord Genuity analyst Matt Bottomley raising his price target on Cronos Group (TSXV:MJN). On Monday, Cronos Group announced it had been granted two medicinal cannabis cultivation and research licences in Australia and wi ...

Provinces need to open up retail pot to private enterprise, Emerald Health CEO says

Emerald Health CEO Chris Wagner   You wouldn’t know it by the frigid temperatures, but summer in Canada is just around the corner, and with only a few months to go before the federal government makes good on its promise to legalize recreational marijuana, there’s still a lot of work to do. W ...